The Influence of Optimal Blood Pressure Control on the Progression of Chronic Kidney Disease
Abstract
Background/Aim: Chronic kidney disease (CKD) has seen a rapid increase worldwide in recent decades, now recognised as a global health issue of the 21st century. Optimal, continuous control of hypertension represents a crucial part of treatment capable of slowing the progression of CKD. The aim of this study was to demonstrate that optimal regulation blood pressure control in patients with essential and secondary hypertension, along with CKD, slows the progression of CKD.
Methods: The research was conducted at the University Clinical Centre of the Republic of Srpska, Banja Luka, Internal Clinic Nephrology Department. A retrospective-prospective study was blind for patients and lasted for 24 months. It included 97 patients, aged 18 and above, of both genders, hypertensive, in the 3rd or 4th stage of CKD (creatinine clearance of 15-59 mL/min). Assess the outcome of CKD, a "complex (undesirable) clinical outcome" was taken - one of three fundamental clinically undesirable events: double increase in serum creatinine values at the end of 24 months, onset of terminal renal insufficiency, or patient death.
Patients were classified into three groups: I group - 30 patients with essential hypertension and CKD with optimally regulated blood pressure; II group - 32 patients with secondary hypertension and CKD with optimally regulated blood pressure; III control group - 35 patients with hypertension of various causes and CKD who did not achieve target blood pressure values. Blood pressure control was measured from month 0 to month 24 - once a month. Laboratory tests were taken every 3 months (red blood cells, haemoglobin, glycaemia, cholesterol, urea, creatinine, uric acid, sodium, potassium in serum and urine).
Results: There was a highly statistically significant difference in glomerular filtration rate in the first group compared to the third group and in the second group compared to the third group. No statistically significant difference in glomerular filtration rate between the first and second groups was observed, where good blood pressure regulation was achieved.
Conclusion: Optimal blood pressure control in the examined groups, regardless of the cause of CKD, was responsible for slowing the progression of CKD compared to the group with unregulated blood pressure.
References
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266. PMID: 11904577.
Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004 May;43(5 Suppl 1):S1-290. PMID: 15114537.
Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007 Nov 7;298(17):2038-47. doi:10.1001/jama.298.17.2038.
Saran R, Robinson B, Abbott KC, Bragg-Gresham J, Chen X, Gipson D, et al. US Renal Data System 2019. Annual data report: Epidemiology of kidney disease in the United States. Am J Kidney Dis. 2020 Jan;75(1 suppl 1):A6-A7. doi:10.1053/j.ajkd.2019.09.003.
Cheng J, Zhang LX. Prevalence and disease burden of chronic kidney disease. Adv Exp Med Biol. 2019;1165:3-15. doi:10.1007/978-981-13-8871-2-1.
Hill N, Fatoba ST, Oke JL, Hirst JA, Callagan C, Lasserson DS, et al. Global prevalence of chronic kidney disease: a systematic review and meta-analysis. PloS One. 2016 Jul 5;11(7):e0158765. doi:10.1371/journal.pone.0158765.
Renal registry of Bosnia and Herzegovina [Internet]. [Renal replacement therapy (RRT) in Bosnia and Herzegovina in 2009. Summary data 2002-2018]. Association of Doctors for Nephrology, Dialysis and Transplantation of Bosnia and Herzegovina: 8-10. [Cited: 1-May-2024]. Available at: https://undt.ba/registar/godisnji-izvjestaji. Bosnian.
Renal registry of Bosnia and Herzegovina [Internet]. [Renal replacement therapy in Bosnia and Herzegovina in 2019. Annual report for 2019]. Association of Doctors for Nephrology, Dialysis and Transplantation of Bosnia and Herzegovina: 7-9. [Cited: 1-May-2024]. Available at: https://undt.ba/registar/godisnji-izvjestaji. Bosnian.
Katičić D, Grbić P, Popac J, Prodanovic G, Vidović L. [Croatian registry of renal function replacement - Report for 2018]. Croatian Society of Nephrology, Dialysis and Transplantation: 8-11. Croatian.
Lameire N, Jager K, Van Biesen W, de Bacquer D, Vanholder R. Chronic kidney disease: a European perspective. Kidney Int Suppl. 2005 Dec;68(99):S30–S38. doi: 10.1111/j.1523-1755.2005.09907.x.
Sarafidis PA, Li S, Chen SC, Collins AJ, Brown WW, Klag MJ, et al. Hypertension awareness, treatment, and control in chronic kidney disease. Am J Med. 2008 Apr;121(4):332-40. doi:10.1016./j.amjmed.2007.11.025.
Obrador GT, Ruthazer R, Arora P, Kausz AT, Pereira BJ. Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States. J Am Soc Nephrol. 1999 Aug;10(8):1793-800. doi:10.1681/ASN.V1081793.
Bidani AK, Griffin KA. Long-term consequences of hypertension for normal and diseased kidneys. Curr Opin Nephrol Hypertens.2002 Jan;11(1):73-80. doi:10.1097/00041552-200201000-0011.
Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med. 2003 Aug 19;139(4):244-52. doi:10.7326/0003-4819-139-4-200308190-00006.
Williams B, Manzia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. Guidelines for the management of arterial hypertension. Eur Heart J. 2018 Sep 1;39(33):3021-104. doi:10.1093/eurhearthj/ehy339.
Kim CS, Choi HS, Bae EH, Kim SW, Ma SK. Optimal blood pressure target and measurement in patients with chronic kidney disease. Korean J Intern Med. 2019 Nov 34(6):1181-7. doi:10.3904/kjim.2019.164.
Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000 Sep;36(3):646-61. doi: 10.1053/ajkd.2000.16225.
Tozawa M, Iseki K, Iseki C, Kinjo K, Ikemiya Y, Takishita S. Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension. 2003 Jun;41(6):1341-45. doi:10.1161/01.HYP.0000069699.92349.8C.
Sarnak MJ, Greene T, Xuelei W, Beck G, Kusek JW, Collins AJ, et al. The effect of lower target blood pressure on the progression of kidney disease: Long-term follow-up of the Modification of Diet in Renal Disease Study. Ann Intern Med. 2005 Mar 1;142(5):342-51. doi:10.7326/0003-4819-142-5-200503010-00009.
ESCAPE Trial Group; Wühl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, Zurowska A, et al. Strict blood-pressure control and progression of renal failure in children. N Engl J Med. 2009 Oct 22;361(17):1639-50. doi: 10.1056/NEJMoa0902066.
Wright Jr JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease, results from the AASK trial. JAMA 2002 Nov 20;288(19):2421-31. doi: 10.1001/jama.288.19.2421.
Ruggenetti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Torturro M, et al. Blood pressure control for renoprotection in patient with nondiabetic chronic renal disease (REIN-2) multicenter, randomized, controlled trial. Lancet. 2005 Mar;365(9463):939-46. doi: 10.1016/S0140-6736(05)71082-5.
Appel L, Wright Jr JT, Greene T, Agodoa LY, Astor BC, Bakris GI, et al. Intensified blood pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010 Sep 2;363(10):918-29. doi:10.1056/NEJMoa0910975.
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).